Pulse Biosciences, Inc. (PLSE) Stock

Pulse Biosciences, Inc. (PLSE) is a Healthcare stock trading at $25.60 (as of 2026-06-18), with a market capitalization of $1.73B and a trailing P/E of -23.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pulse Biosciences, Inc. develops bioelectric therapies using its Nano-Pulse Stimulation technology, delivered through its CellFX System. The company’s software-enabled platform delivers brief electrical pulses to targeted cells for the non-thermal treatment of medical conditions, aiming to spare surrounding non-cellular tissue for patients.

Valuation — source: SEC EDGAR (first-party)

Price	$25.60
Market Cap	$1.73B
P/E Ratio	-23.2
EV / EBITDA	-21.4
Price / Book	26.10
Price / Sales	2303.92
DCF Value (model)	$-12.40
DCF Upside vs Price	-148.4%

Profitability & Growth — source: SEC EDGAR

Revenue (TTM)	$350000.00
Net Margin	-20794.6%
Return on Equity	-112.5%
Current Ratio	7.26

Financial Health — source: SEC EDGAR

Altman Z-Score

66.90 (safe)

Valuation vs Sector & Industry

Stock P/E	-23.2
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-210.7%
vs Industry	-173.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures

Top Institutional Holder	BlackRock, Inc. ($28.93M)
Institutional Holders Tracked	10

Company

Sector	Healthcare
Industry	Medical Equipment
CEO	Paul Arthur LaViolette
Employees	75
Country	US
IPO Date	2016-05-18

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

• SS Innovations International, Inc. (SSII)
• MiMedx Group, Inc. (MDXG)
• Integra LifeSciences Holdings Corporation (IART)
• Butterfly Network, Inc. (BFLY)
• InMode Ltd. (INMD)
• SI-BONE, Inc. (SIBN)
• Embecta Corp. (EMBC)
• CeriBell, Inc. (CBLL)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.